JPH10310527A - Pharmaceutical - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain the subject pharmaceutical preparation having excellent physiological activity such as humectant action and useful especially for dermal surgery by including primeverose as an essential component. SOLUTION: The objective pharmaceutical preparation effective for ameliorating dermatic diseases such as xeroderma and atopic dermatitis can be produced by including (A) 0.01-20 wt.%, preferably 0.05-15 wt.%, especially 0.1-10 wt.% of primeverose produced e.g. by an enzymatic synthesis having excellent stereoselectivity by reacting xylobiose with glucose at a molar ratio of 2:1 in the presence of a pectinase at 40 deg.C for 24 hr and heating the reaction product for 5 min and (B) a drug active component (e.g. antiinflammatory agent, antibacterial agent, coronary vasodilator and other humectant).

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to a pharmaceutical product having an excellent moisturizing action.

[0002]

BACKGROUND OF THE INVENTION Primeverose is a glucopyranose 6
Glycosides are known, which are disaccharides in which the position and the first position of xylose are condensed by an ether bond, and in nature, an aglycone such as terpene is bonded to the first position of primeverose. Primeverose itself is known to exist, but its properties and actions are not known. In particular, it is not known that this substance is useful as a moisturizing component. Further, it has not been known that premeverose is contained in pharmaceuticals and the like.

[0003] On the other hand, moisturizing components play a very important role in the manifestation of their effects in pharmaceuticals. From such a viewpoint, development of various moisturizing components has been attempted.
Sodium hyaluronate and acrylic acid copolymers have been developed. However, there are many factors related to the moisturizing effect, and even if a certain moisturizing component is effective for a certain person, the other person does not exhibit such a significant effect. I was In addition, many saccharides, such as trehalose and sialic acids, have an effect on physiological activity, and development of saccharides useful for living organisms has been desired. Particularly in pharmaceuticals, it is known that there is an interaction between a sugar as an excipient and a medicinal ingredient, and the stability of the medicinal ingredient is impaired or improved depending on the type of sugar. It is known that there are things. From this point of view, development of excipients that improve the stability of medicinal ingredients without impairing them has been desired.

[0004]

SUMMARY OF THE INVENTION The present invention has been made under such circumstances, and it is an object of the present invention to provide a drug having excellent physiological activity such as moisturizing action.

[0005]

In view of such circumstances, the present inventors have conducted intensive studies for saccharides having beneficial physiological activities such as moisturizing action and pharmaceuticals containing the same, and as a result, have found that primeverose has been Find it works,
The invention has been completed.

[0006] That is, the present invention is a medicine characterized by containing primeverose. Further, the present invention is the above-mentioned pharmaceutical product, wherein the application site is skin. Further, the content of premeverose is 0.01 to 2
0% by weight.

Hereinafter, the present invention will be described in detail focusing on embodiments of the invention.

[0008]

BEST MODE FOR CARRYING OUT THE INVENTION

(1) Premeverose used in the present invention Primeverose used in the present invention is a disaccharide in which a 6-position hydroxyl group of β-D-glucopyranose and a 1-position hydroxyl group of xylose are ether-bonded. It is known that a glycoside in which the hydroxyl group at position 1 is bonded to aglycone is present. Primeverose itself is a known substance, but its properties are not yet well known. In chemical synthesis, for example,
It can be obtained by reacting 1,2,3,4-tetraacetylglucose with acetobromoxylose using silver nitrate or the like as a catalyst. In the case of enzymatic synthesis, D-glucose and xylobiose can be obtained by the reaction of an enzyme such as pectinase. It can be obtained by the existence condensation. Among these production methods, a preferable one is an enzyme synthesis method having excellent stereoselectivity. Hereinafter, examples of the enzyme synthesis method will be described.

<Production Example> Xylobiose and glucose were reacted in a 100 mM citrate phosphate buffer (pH 3.0) at 40 ° C. for 24 hours in the presence of pectinase (1.5 U / ml) at a molar ratio of 1: 2. Thereafter, the reaction was stopped by heating for 5 minutes. The reaction solution was purified by column chromatography using activated carbon-celite equilibrated with water as a carrier (elution solvent: water: ethanol = 100: 0 → 70:
30) Then, recrystallization from ethanol yielded 6.35% yield of primeverose per 42 mg of xylobiose.

[0010] The premeverose used in the present invention has an excellent moisturizing action on the skin, and by applying it, various symptoms mainly caused by insufficient moisturizing can be alleviated. These symptoms include, for example,
Skin diseases such as xeroderma and atopic dermatitis can be exemplified. The preferred content of primeverose in the drug of the present invention is slightly different depending on the use, but is preferably 0.01 to 20% by weight, more preferably 0.05 to 15% by weight, and still more preferably 0.1 to 15% by weight. 10% by weight.

(2) Pharmaceutical of the present invention The pharmaceutical of the present invention is characterized by containing the above-mentioned premeverose. The drug of the present invention can be a drug for external use on the skin whose application site is skin, and other drugs, but it is particularly preferable to be a drug for external use on the skin. This is because the excellent moisturizing action of Primeverose can be preferably applied. The medicament of the present invention can contain a medicinal ingredient other than primeverose, for example, anti-inflammatory agents such as tenoxicam, indomethacin, ketotefen, ketoprofen, bufexamac, prednisolone, butenafine, terbinafine, miconazole nitrate, econazole nitrate, tolnaftate, pyrrole. Antimicrobial agents such as nitrin and clotrimazole, antiviral agents such as sorivudine, acyclovir, ganciclovir, and coronary vasodilators such as nifedipine, diltiazem, and verapamil can be suitably included. Further, the pharmaceutical composition of the present invention may contain moisturizing components other than primeverose, such as sodium hyaluronate, sodium chondroitin sulfate, placental extract, trehalose, and sodium sulfated trehalose. Furthermore, the drug of the present invention can contain, as a constituent, an optional component usually used in a drug.
Such optional components include, for example, in the case of a topical skin drug, hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and gay wax, triglycerides such as tallow, olive oil, cetanol, and oleyl. Higher alcohols such as alcohol, fatty acids such as stearic acid and oleic acid, glycerin and 1,3
Polyhydric alcohols such as butanediol, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, ethanol, thickeners such as carbopol,
Examples include preservatives, ultraviolet absorbers, antioxidants, pigments, powders, vitamins, and the like. In addition, if the drug is a drug other than a topical skin drug, excipients, binders, coating agents, lubricants, sugar coatings, disintegrants, bulking agents, flavoring agents, emulsifying / solubilizing / dispersing agents, stabilizers, Examples thereof include a pH adjuster and an isotonic agent.

The medicament of the present invention can be produced by processing these optional components and premeverose according to a conventional method. The drug thus obtained is, for example, a drug for external use on the skin, and is excellent in improvement and healing of skin inflammation and the like due to its excellent moisturizing action. In addition, the drug of the present invention, including drugs other than topical skin drugs, is also excellent in stability of content components.

[0013]

The present invention will be described in more detail with reference to the following examples, but it goes without saying that the present invention is not limited to these examples.

Example 1 Formulation Example An anti-inflammatory cream was prepared according to the formulation shown in Table 1. That is, "A" was kneaded, "B" was added and diluted, heated to 80 ° C, "C" was gradually added and emulsified, stirred and cooled to obtain an anti-inflammatory cream.

[0015]

[Table 1]

Example 2 Formulation Example An antifungal cream was prepared according to the formulation shown in Table 2. That is, "A" was kneaded, "B" was added and diluted, heated to 80 ° C, "C" was gradually added and emulsified, stirred and cooled to obtain an antifungal cream.

[0017]

[Table 2]

Example 3 Formulation Example An anti-inflammatory cream was prepared according to the formulation shown in Table 3. That is, "A" was kneaded, "B" was added and diluted, heated to 80 ° C, "C" was gradually added and emulsified, stirred and cooled to obtain an anti-inflammatory cream.

[0019]

[Table 3]

Example 4 Formulation Example An antiviral cream was prepared according to the formulation shown in Table 4. That is, knead “a”, add “b” and dilute to 8
The mixture was heated to 0 ° C., and “C” was gradually added thereto to emulsify and cool with stirring to obtain an antiviral cream.

[0021]

[Table 4]

Example 5 Formulation Example Granules were prepared according to the formulation shown in Table 5. That is, A was granulated by extrusion granulation, blow-dried at 40 ° C. for 24 hours, and then rolled with a mulmerizer to obtain granules. This was dissolved in 500 parts by weight of a mixed solution of an equal amount of methylene chloride and ethanol, and coated with a plummarizer. The solvent was removed by blowing at 40 ° C. to obtain granules. It was stable at 40 ° C. for 6 months.

[0023]

[Table 5] Eudragit E-100 (trade name, manufactured by Laem Pharma)

[0024]

The drug of the present invention is excellent in beneficial physiological activities such as moisturizing action, and also excellent in stability of the contents.

────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. ⁶ Identification symbol FI // C07H 3/02 C07H 3/02 (72) Inventor Kanzo Sakata 836 Otani, Shizuoka City, Shizuoka Prefecture Shizuoka University Faculty of Agriculture (72) Invention Person Yasushi Usui 836 Otani, Shizuoka City, Shizuoka Prefecture Inside the Faculty of Agriculture, Shizuoka University (72) Inventor Shuji Watanabe 836 Otani, Shizuoka City, Shizuoka Prefecture, Shizuoka University

Claims (3)

[Claims] 1. A medicament characterized by containing primeverose. 2. The drug according to claim 1, wherein the application site is skin. 3. The method according to claim 1, wherein the content of primeverose is 0.01 to 2
The medicament according to claim 1 or 2, which is 0% by weight.